Accounting for Nonadherence

Circulation. 2018 May 15;137(20):2139-2141. doi: 10.1161/CIRCULATIONAHA.118.033532.

Authors

Erica S Spatz^{1

2}, Jeptha P Curtis^{3

2}

Affiliations

¹ Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (J.P.C., E.S.S.).
² Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.P.C., E.S.S.).
³ Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (J.P.C., E.S.S.) jeptha.curtis@yale.edu.

PMID: 29760226
DOI: 10.1161/CIRCULATIONAHA.118.033532

No abstract available

Keywords: Editorials; drugs; myocardial infarction; pharmacology; prevention; statins.

Publication types

Editorial
Comment

MeSH terms

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Myocardial Infarction*
Secondary Prevention

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors